Literature DB >> 26235779

Primary drug resistance in a region with high burden of tuberculosis. A critical problem.

Cecilia Villa-Rosas1, Rafael Laniado-Laborín1, Lorena Oceguera-Palao1.   

Abstract

OBJECTIVE: To determine rates of drug resistance in new cases of pulmonary tuberculosis in a region with a high burden of the disease.
MATERIALS AND METHODS: New case suspects were referred for drug susceptibility testing.
RESULTS: 28.9% of new cases were resistant to at least one first line drug; 3.9% had a multidrug-resistant strain, 15.6% a monoresistant strain and 9.4% a polyresistant strain.
CONCLUSION: Our rate of drug resistant tuberculosis in new cases is very high; this has important clinical implications, since even monoresistance can have a negative impact on the outcome of new cases treated empirically with a six month regimen.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26235779     DOI: 10.21149/spm.v57i2.7414

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  4 in total

1.  Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010.

Authors:  Renata Báez-Saldaña; Guadalupe Delgado-Sánchez; Lourdes García-García; Luis Pablo Cruz-Hervert; Marlene Montesinos-Castillo; Leticia Ferreyra-Reyes; Miriam Bobadilla-Del-Valle; Sergio Canizales-Quintero; Elizabeth Ferreira-Guerrero; Norma Téllez-Vázquez; Rogelio Montero-Campos; Mercedes Yanes-Lane; Norma Mongua-Rodriguez; Rosa Areli Martínez-Gamboa; José Sifuentes-Osornio; Alfredo Ponce-de-León
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

2.  Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia.

Authors:  Melaku Tilahun; Gobena Ameni; Kassu Desta; Aboma Zewude; Lawrence Yamuah; Markos Abebe; Abraham Aseffa
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

3.  Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru.

Authors:  Leonela Villegas; Larissa Otero; Timothy R Sterling; Moises A Huaman; Patrick Van der Stuyft; Eduardo Gotuzzo; Carlos Seas
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

4.  Effects of secondary infections on the multidrug-resistant Tuberculosis: A cohort study.

Authors:  Nurlan Tabriz; Zhanara B Nurtazina; Margulan T Kozhamuratov; Kuliya Skak; Zhumat Mutaikhan
Journal:  Med J Islam Repub Iran       Date:  2021-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.